DXCM vs. NVO
DXCM (DexCom, Inc.) and NVO (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — DXCM in Diagnostics & Research, NVO in Drug Manufacturers - General. Over the past 10 years, DXCM returned 15.17%/yr vs 7.56%/yr for NVO. At a 0.24 correlation, their price movements are largely independent.
Performance
DXCM vs. NVO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, DXCM achieves a 13.56% return, which is significantly higher than NVO's -10.74% return. Over the past 10 years, DXCM has outperformed NVO with an annualized return of 15.17%, while NVO has yielded a comparatively lower 7.56% annualized return.
DXCM
- 1D
- 0.16%
- 1M
- 28.68%
- YTD
- 13.56%
- 6M
- 12.56%
- 1Y
- -9.03%
- 3Y*
- -15.73%
- 5Y*
- -5.51%
- 10Y*
- 15.17%
NVO
- 1D
- -0.18%
- 1M
- -6.80%
- YTD
- -10.74%
- 6M
- -9.50%
- 1Y
- -43.34%
- 3Y*
- -15.59%
- 5Y*
- 2.92%
- 10Y*
- 7.56%
DXCM vs. NVO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
DXCM DexCom, Inc. | 13.56% | -14.66% | -37.33% | 9.58% | -15.64% | 45.23% | 69.02% | 82.59% | 108.75% | -3.87% |
NVO Novo Nordisk A/S | -10.74% | -39.22% | -15.93% | 54.84% | 22.66% | 63.52% | 23.33% | 28.70% | -12.98% | 52.92% |
Correlation
The correlation between DXCM and NVO is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.20 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.15 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.23 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.24 |
Correlation (All Time) Calculated using the full available price history since Apr 14, 2005 | 0.24 |
Fundamentals
DXCM:
$29.67B
NVO:
$195.21B
DXCM:
$2.31
NVO:
DKK 27.42
DXCM:
32.57
NVO:
10.34
DXCM:
0.77
NVO:
0.44
DXCM:
6.29
NVO:
3.85
DXCM:
10.03
NVO:
6.21
DXCM:
$4.82B
NVO:
DKK 327.80B
DXCM:
$2.96B
NVO:
DKK 268.30B
DXCM:
$1.37B
NVO:
DKK 181.54B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DXCM vs. NVO — Risk / Return Rank
DXCM
NVO
DXCM vs. NVO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for DexCom, Inc. (DXCM) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DXCM | NVO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.62 | ||
| Sortino ratioReturn per unit of downside risk | +1.01 | ||
| Omega ratioGain probability vs. loss probability | 1.00 | 0.85 | +0.14 |
| Calmar ratioReturn relative to maximum drawdown | -0.23 | -0.80 | +0.57 |
| Martin ratioReturn relative to average drawdown | -0.40 | -1.18 | +0.78 |
Loading charts...
Drawdowns
DXCM vs. NVO - Drawdown Comparison
The maximum DXCM drawdown since its inception was -94.61%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for DXCM and NVO.
Loading charts...
Drawdown Indicators
| DXCM | NVO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.61% | -74.70% | -19.91% |
Max Drawdown (1Y)Largest decline over 1 year | -38.75% | -54.34% | +15.59% |
Max Drawdown (3Y)Largest decline over 3 years | -60.95% | -74.70% | +13.75% |
Max Drawdown (5Y)Largest decline over 5 years | -66.32% | -74.70% | +8.38% |
Max Drawdown (10Y)Largest decline over 10 years | -66.32% | -74.70% | +8.38% |
Current DrawdownCurrent decline from peak | -53.71% | -68.11% | +14.40% |
Average DrawdownAverage peak-to-trough decline | -36.02% | -17.79% | -18.23% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 22.77% | 37.62% | -14.85% |
Volatility
DXCM vs. NVO - Volatility Comparison
DexCom, Inc. (DXCM) has a higher volatility of 13.27% compared to Novo Nordisk A/S (NVO) at 10.68%. This indicates that DXCM's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DXCM | NVO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 13.27% | 10.68% | +2.59% |
Volatility (6M)Calculated over the trailing 6-month period | 25.48% | 38.04% | -12.56% |
Volatility (1Y)Calculated over the trailing 1-year period | 40.74% | 51.88% | -11.14% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 46.98% | 38.33% | +8.65% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 48.43% | 32.56% | +15.87% |
Dividends
DXCM vs. NVO - Dividend Comparison
DXCM has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.11%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DXCM DexCom, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
NVO Novo Nordisk A/S | 4.11% | 3.31% | 1.68% | 1.00% | 1.20% | 1.35% | 1.87% | 2.14% | 1.45% | 1.52% | 2.87% | 0.92% |
Financials
DXCM vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between DexCom, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
DXCM vs. NVO - Profitability Comparison
DXCM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported a gross profit of 750.30M and revenue of 1.19B. Therefore, the gross margin over that period was 63.0%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.
DXCM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported an operating income of 255.30M and revenue of 1.19B, resulting in an operating margin of 21.4%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.
DXCM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, DexCom, Inc. reported a net income of 199.50M and revenue of 1.19B, resulting in a net margin of 16.7%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.
Frequently Asked Questions
DXCM and NVO have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
DXCM has higher volatility (13.27%) compared to NVO (10.68%). In terms of maximum drawdown, DXCM dropped -94.61% vs NVO's -74.70%.
DXCM currently has the higher Sharpe Ratio (-0.22 vs -0.84), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for DXCM and NVO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer